公司财务表现 - 礼来公司2025年第一季度营收达到198亿美元，同比增长55.5%，超出市场预期11.25% [1][7] - 第一季度非美国通用会计准则每股收益为8.55美元，比市场共识6.79美元高出25.88% [1][7] - 公司上调了全年业绩指引，预计营收在820亿至850亿美元之间，每股收益在35.5至37美元之间 [1][7] 核心产品业绩 - 糖尿病药物Mounjaro第一季度销售额达86.6亿美元，同比增长125% [1][7] - 减肥药Zepbound第一季度贡献了41.6亿美元收入，同比增长80% [1][7] - 口服GLP-1药物Foundayo获得美国FDA批准，这是唯一获批的可灵活给药、无需饮食限制的口服GLP-1药丸，有望大幅扩展可触及的肥胖症市场 [8] 股价与估值分析 - 24/7 Wall St.给出的未来12个月目标价为1,133.12美元，较当前股价934.60美元有21.24%的上涨空间 [4][5] - 尽管业绩强劲，公司股价年初至今下跌了12.89%，从2025年12月约1,062美元的高点回落 [2][6] - 看涨情景下的目标价可达1,219.94美元，意味着30.53%的总回报率 [9] - 分析师普遍看涨，共识目标价为1,202.34美元，有24个买入评级和1个卖出评级 [9] 研发与管线进展 - 药物Retatrutide的3期数据显示其在2型糖尿病治疗中能显著降低A1C和体重 [9] - Mounjaro被纳入中国国家医保药品目录，预计将提升销量但可能降低国际单剂价格 [9][11] - 公司通过四笔已宣布的收购（Orna, Centessa, Kelonia, Ajax）将管线扩展至细胞疗法和CAR-T领域 [9] 长期增长前景 - 基于当前增长轨迹和利润率指引，模型预测公司股价到2030年可能达到1,674.95美元 [14] - 长期增长将取决于口服GLP-1药物的市场份额增长、生物类似药上市时间以及主要市场的定价让步情况 [14] - 公司被视为有望成为下一个市值万亿美元的股票，目前市值约为8,150亿美元 [19][20]

Still life of the new Wegovy semaglutide tablets on a white background. Its a prescription medicine used with a reduced calorie diet and .and physical activity. When the Wegovy pill launched in January, telehealth provider LifeMD said its business doubled almost overnight. Doubts about Lilly's lock on the market emerged last summer when the company said its pill helped people lose about 12% of their body weight, on average. Seigerman noticed Novo pounced on the opportunity and started to highlight the effic ...

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is one of Cramer's favorite stocks in the space. The shares are up by 16.9% over the past year and are down by 10.8% year-to-date. The stock closed 9.8% higher on April 30th as the firm reported its first-quarter earnings. The results saw Eli Lilly and Company (NYSE:LLY) post $19.8 billion in revenue and $8.55 in earnings per share to beat analyst estimates of $6.66. Cramer has praised the firm for multiple reasons for more than a year. These include a r ...

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about expected dividend payments and reflects Lilly's current beliefs and expectations. However, there are significant risks and uncertainties in pharmaceutical research and development, as well as in business development activities and capital allocation strategies related to the company's business and actual result ...

The Food and Drug Administration has recorded two 'serious' cases in patients taking Eli Lilly's weight-loss pill. ...

I keep buying Eli Lilly (NYSE:LLY | LLY Price Prediction), and the latest quarter just made it harder to stop. ...

Quick Read I keep buying Eli Lilly (NYSE:LLY), and the latest quarter just made it harder to stop. This is a confession of conviction. I have been adding through every dip in 2026, and the most recent earnings report told me the thesis is accelerating. What pulls me back to the buy button is simple. Lilly sits at the center of the largest therapeutic shift in modern medicine, the GLP-1 build-out for diabetes and obesity, and it is the only company with a metabolic franchise this deep, this fast-growing, and ...

礼来公司股价盘前下跌3%。 ...

Drugs that target obesity and diabetes now account for an estimated 38% of all projected commercial inflows from the 2025 late-stage pipeline. Surging demand for weight loss and diabetes drugs leaves the pharmaceutical sector at risk from a "bubble effect" as profitability soars, new research suggests. Demand for the likes of Wegovy and Zepbound has driven research and development returns to their highest level in years, but a report published by Deloitte on Monday suggests this is masking pressure facing t ...

Eli Lilly's (NYSE: LLY) broad range of drugs has helped build its success over time, but in recent years, one particular portfolio has supercharged growth. I'm talking about the company's weight loss drugs. The key product is tirzepatide, sold under the names Mounjaro for type 2 diabetes and Zepbound for weight loss. They are part of the GLP-1 class of drugs that have taken the world by storm -- demand for these products has been so high at times that it's even created supply shortages. (Supply is fine now, ...